HBV-specific T-cell Immunity in Individuals With HIV/HBV Co-infection

The HIV Netherlands Australia Thailand Research Collaboration

Status: Completed

Conditions: Hepatitis-B; HIV

Study type: Observational

Funder types: Other

Identifiers

NCT00476723

HIV-NAT 032

Details and patient eligibility

About

The trial will randomise HIV/HBV co-infected individuals to different HBV-active antiretroviral therapy treatment regimens.

Full description

Longitudinal study of circulating and intra-hepatic HBV-specific T-cell immunity in the setting of a randomised, controlled, international, multi-centre outpatient trial. The trial will randomise HIV/HBV co-infected individuals to different HBV-active antiretroviral therapy treatment regimens.

Study population: Patients with HIV/HBV co-infection who are naive to HIV/HBV therapy, have detectable HBV viremia and are willing to start antiretroviral therapy.

Enrollment: 36 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV positive
• hepatitis-B co-infected
• HBV/HIV therapy naive
• >18 years of age

Exclusion criteria

Unable to sign consent form.

Trial design

36 participants in 1 patient group

1

Description:

HIV/Hepatitis coinfected patients who use at least one hepatitis activity drug or medications